Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial

被引:93
作者
Riecke, B. F. [1 ]
Christensen, R. [1 ]
Christensen, P. [1 ]
Leeds, A. R. [2 ,3 ,4 ,5 ]
Boesen, M. [1 ]
Lohmander, L. S. [6 ]
Astrup, A. [5 ]
Bliddal, H. [1 ]
机构
[1] Frederiksberg Univ Hosp, Parker Inst, DK-2000 Copenhagen F, Denmark
[2] Univ Surrey, London, England
[3] N London Obes Surg Serv, London, England
[4] Cent Middlesex Hosp, Middlesex, England
[5] Univ Copenhagen, Fac Life Sci, Dept Human Nutr, DK-1168 Copenhagen, Denmark
[6] Lund Univ, Dept Orthoped, S-22100 Lund, Sweden
关键词
Knee osteoarthritis; Weight-loss; Diet; Randomized clinical trial; OUTCOME SCORE KOOS; WEIGHT-LOSS; OLDER-ADULTS; MANAGEMENT; ARTHRITIS; PAIN; RECOMMENDATIONS; METAANALYSIS; REDUCTION; EXERCISE;
D O I
10.1016/j.joca.2010.02.012
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives To evaluate in a prospective, randomized clinical trial (RCT), symptom response among obese knee osteoarthritis (OA) patients following a feasible. intensive weight-loss program for 16 weeks Methods Eligible patients were obese [body mass index (BMI)> 30 kg/m(2)], >50 years old, with primary knee OA Participants were randomized to either a very-low-energy diet (VLED) or a low-energy diet (LED) (415 kcal/day and 810 kcal/clay, respectively), using commercially available formula foods only for the first 8 weeks, managed by dieticians The 8 weeks were followed by an additional 8-week period of a hypo-energetic diet consisting of normal food plus meal replacements (1200 kcal/day) The primary endpoint was the number of patients responding according to the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) responder criterion The statistical analysis was based on a non-responder intention-to-treat gro population (baseline observation carried forward) Results One hundred and ninety two patients (155 (80 7%) females) with a mean age 62 5 years [standard deviation (SD) 64, range 50-78 years), average BMI 37.3 (SD 4 8) were included At 16 weeks, similar proportions of the VLED and LED groups, 59 (61 5%). and 63 (65.6%) patients, respectively, met the OMERACT-OARSI responder criteria, with no statistical significant difference between the groups (P=0 55) Combining the groups the pooled estimate was 64% meeting the responder criteria [95% confidence interval (CI) 57%. 70%] There was an overall reduction in pain, corresponding to an average pain reduction on the visual analogue scale (VAS) of 111 (95%CI 13 6, 8 5) in the combined groups At week 16 weight loss in the combined groups was 128 kg (95%CI 11 84-13 66, P < 0 001) 71% lost >= 10% body weight in both diet groups, with a pooled estimate of 74% (95%CI 68-80%) Conclusion No clinically significant differences were found between the 415 kcal/day and 810 kcal/clay diets A 16-week formula-diet weight-loss program resulted in a fast and effective weight loss with very few adverse events resulting in a highly significant improvement in symptoms in overweight patients with knee OA ChnicalTrials gov Identifier NCT00655941 (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved
引用
收藏
页码:746 / 754
页数:9
相关论文
共 40 条
[1]   Treatment allocation by minimisation [J].
Altman, DG ;
Bland, JM .
BRITISH MEDICAL JOURNAL, 2005, 330 (7495) :843-843
[2]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[3]   DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE [J].
ALTMAN, R ;
ASCH, E ;
BLOCH, D ;
BOLE, G ;
BORENSTEIN, D ;
BRANDT, K ;
CHRISTY, W ;
COOKE, TD ;
GREENWALD, R ;
HOCHBERG, M ;
HOWELL, D ;
KAPLAN, D ;
KOOPMAN, W ;
LONGLEY, S ;
MANKIN, H ;
MCSHANE, DJ ;
MEDSGER, T ;
MEENAN, R ;
MIKKELSEN, W ;
MOSKOWITZ, R ;
MURPHY, W ;
ROTHSCHILD, B ;
SEGAL, M ;
SOKOLOFF, L ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1986, 29 (08) :1039-1049
[4]   Measurement of structural progression in osteoarthritis of the hip: the Barcelona consensus group [J].
Altman, RD ;
Bloch, DA ;
Dougados, M ;
Hochberg, M ;
Lohmander, S ;
Pavelka, K ;
Vignon, E .
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 (07) :515-524
[5]  
[Anonymous], 2000, WHO TECHN REP SER, V894, pi, DOI DOI 10.1596/0-1952-1129-4
[6]   Dietary approaches to reducing body weight [J].
Astrup, A .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 13 (01) :109-120
[7]   Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials [J].
Bjordal, JM ;
Ljunggren, AE ;
Klovning, A ;
Slordal, L .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478) :1317-1320D
[8]   The management of osteoarthritis in the obese patient: practical considerations and guidelines for therapy [J].
Bliddal, H. ;
Christensen, R. .
OBESITY REVIEWS, 2006, 7 (04) :323-331
[9]   Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial [J].
Christensen, R ;
Astrup, A ;
Bliddal, H .
OSTEOARTHRITIS AND CARTILAGE, 2005, 13 (01) :20-27
[10]   Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [J].
Christensen, Robin ;
Kristensen, Pernelle Kruse ;
Bartels, Else Marie ;
Blidda, Henning ;
Astrup, Arne .
LANCET, 2007, 370 (9600) :1706-1713